EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Long‐term effectiveness of eculizumab: Data from the International PNH Registry

Louis Terriou, Jong Wook Lee, Cecily Forsyth, Morag Griffin, Jeff Szer iD, Alexander Röth, Philippe Gustovic, Jesse Metzger, Ami S Patel, Christopher J Patriquin iD

European Journal of Haematology · 2023-11 · 111 (5) · 796-804

DOI: 10.1111/ejh.14080 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Haematology, online erschienen am 15.09.2023. Verfasst von Louis Terriou und 9 weiteren Autor:innen. Beteiligte Einrichtung: Université de Lille, Inserm, CHU Lille, Service de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Autoimmunes Systémiques…. Hauptthemen laut MEDLINE: Hemoglobinuria, Paroxysmal. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Alexion, AstraZeneca Rare Disease, Alexion Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Data from the International PNH Registry (NCT01374360) were used to estimate the overall survival and first occurrence of thromboembolic events/major adverse vascular events (TEs/MAVEs) for eculizumab‐treated patients with paroxysmal nocturnal hemoglobinuria (PNH) compared with a contemporaneous untreated cohort.

Methods

Patients enrolled in the Registry from March 16, 2007, to February 14, 2022, were included. Treated patients received eculizumab for >35 days; untreated patients did not receive eculizumab at any time. Univariable and multivariable analyses were performed using a Cox proportional hazards regression model comparing eculizumab treatment periods to untreated periods and were adjusted for baseline covariates (e.g., high disease activity [HDA], transfusion dependency, and eculizumab treatment status).

Results

The analysis included 4118 patients. The univariable hazard ratio (HR) (95% CI) for mortality in eculizumab‐treated time versus untreated time was 0.51 (0.41–0.64; p < 0.0001). Significant baseline covariates included age, sex, history of bone marrow failure, ≥4 erythrocyte transfusions within 12 months before baseline, and an estimated glomerular filtration rate ≤ 60 mL/min/1.73 m 2 (all p < 0.0001). In the adjusted analysis, patients with baseline HDA had the greatest reduction in mortality risk (HR [95% CI], 0.51 [0.36–0.72]). Treated patients had approximately 60% reduction in TE/MAVE risk during treated versus untreated time (HR [95% CI]: TE: 0.40 [0.26–0.62], MAVE: 0.37 [0.26–0.54]; p < 0.0001).

Conclusion

Using data from the largest Registry of patients with PNH, with ≥14 years of overall follow‐up, we demonstrate that treatment with eculizumab conferred a 49% relative benefit in survival and an approximately 60% reduction in TE/MAVE risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemoglobinuria, ParoxysmalHumansInfantAntibodies, Monoclonal, HumanizedErythrocyte TransfusionRegistries

Stichwörter der Autor:innen

C5 inhibitorPNH Registrymajor adverse vascular eventsreal-worldsurvivalthromboembolic events

Substanzen

eculizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Université de Lille, Inserm, CHU Lille, Service de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Autoimmunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Institut de Recherch…
  • Department of Hematology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea.
  • Central Coast Haematology, North Gosford, New South Wales, Australia.
  • Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
  • Department of Clinical Haematology, Peter MacCallum Cancer Centre and the Royal Melbourne Hospital, Melbourne, Victoria, Australia.
  • Department of Hematology and Stem Cell Transplantation, University Hospital Essen and University of Duisburg-Essen, Essen, Germany.

ORCID-Profile: Jeff Szer, Christopher J Patriquin

Förderung

  • Alexion, AstraZeneca Rare Disease
  • Alexion Pharmaceuticals

Zitieren

APA

Terriou, L., Lee, J. W., Forsyth, C., Griffin, M., Szer, J., Röth, A., Gustovic, P., Metzger, J., Patel, A. S., & Patriquin, C. J. (2023). Long‐term effectiveness of eculizumab: Data from the International PNH Registry. European Journal of Haematology, 111(5), 796-804. https://doi.org/10.1111/ejh.14080

Vancouver

Terriou L, Lee JW, Forsyth C, Griffin M, Szer J, Röth A, et al. Long‐term effectiveness of eculizumab: Data from the International PNH Registry. European Journal of Haematology. 2023;111(5):796-804. doi:10.1111/ejh.14080

BibTeX
@article{Terriou2023,
  author = {Terriou, Louis and Lee, Jong Wook and Forsyth, Cecily and Griffin, Morag and Szer, Jeff and Röth, Alexander and Gustovic, Philippe and Metzger, Jesse and Patel, Ami S and Patriquin, Christopher J},
  title = {Long‐term effectiveness of eculizumab: Data from the International PNH Registry},
  journal = {European Journal of Haematology},
  year = {2023},
  volume = {111},
  number = {5},
  pages = {796--804},
  doi = {10.1111/ejh.14080}
}
Kostenlos starten →